Green leaf pharmaceutical in the research of new drug Liss permeable skin patch (multi-day patch) approved for clinical trials in China.

Liss's permeable patch (multi-day patch) is a key product for central nervous system diseases and was developed by the company's German subsidiary, Luye Pharma AG, which is protected globally by multiple patents.
Luye Pharma AG is one of the largest manufacturers of independent permeable systems in Europe, with a highly complex process and high technical barriers to the production of permeable agents that have passed the Good Manufacturing Practices (GMP) inspections in the United States, the European Union and Japan.
Luye Pharma AG's Liss permeable patch (one-day patch) has been approved for listing in more than 20 countries around the world, including some countries in the United States and Europe, and is the first to be approved for sale in China in accordance with the quality and efficacy consistency evaluation review requirements.
Compared to the one-day patch, Liss's permeable patch (multi-day patch) is given twice a week, reducing the frequency of drug use, can effectively improve the patient's drug compliance, reduce the care burden of caregivers while reducing the socio-economic burden.
's application for the listing of the permeable patch (multi-day patch) has been formally accepted by seven European countries, including Germany, the United Kingdom, Spain, Italy, Portugal, Luxembourg and Greece, and the relevant review work has been carried out smoothly.
addition to Europe and China, the Company intends to register the product in the United States, Japan and other countries.
.